New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide–Human Leukocyte Antigen (HLA)-A*02:01 complex (NY-ESO-1–HLA complex)

The New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide–HLA complex is a highly specific cancer-testis antigen (CTA) target used in advanced immunotherapy [6]. NY-ESO-1 is expressed in a variety of solid and hematologic malignancies, such as synovial sarcoma, melanoma, and multiple myeloma, but is absent from normal adult tissues except for the testis and placenta [5, 10]. The target consists of an intracellularly processed peptide, typically the SLLMWITQC epitope, presented on the cell surface by the Human Leukocyte Antigen (HLA)-A*02:01 molecule [4, 11]. Engineered Natural Killer (NK) cells expressing a T-cell receptor (T}

Other names

CTAG1BCancer/testis antigen 1BNY-ESO-1HLA-A2/NY-ESO-1 complexSLLMWITQC peptide–HLA-A*02:01 complexNY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted complex

TCR-mediated recognition of the NY-ESO-1 peptide–HLA complex on tumor cells, triggering cytotoxic activity and cytokine release by the engineered NK cells.